New drug ANXV shows promise for common eye diseases in early trial
NCT ID NCT07259928
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ANXV in 12 adults with eye diseases from diabetes or blocked retinal veins. The main goal is to check if ANXV is safe and if it can improve vision or reduce the need for other treatments. Participants receive ANXV as a 30-minute infusion for 5 days and are followed for 4 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-PROLIFERATIVE DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Retina Clinic London
RECRUITINGLondon, W1G9AX, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Herbal formula plus eye injections: a new hope for blocked retinal veins?
- New eye drug aims to stop diabetic vision loss
- Scientists hunt for new eye disease marker in fluid samples
- New syringe for eye disease injections passes usability test
- Could a cotton swab replace the metal speculum for eye injections?
- New eye drug shows promise for diabetic vision loss